0001415889-24-003891.txt : 20240215
0001415889-24-003891.hdr.sgml : 20240215
20240215160555
ACCESSION NUMBER: 0001415889-24-003891
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240213
FILED AS OF DATE: 20240215
DATE AS OF CHANGE: 20240215
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Jimenez Freddy A.
CENTRAL INDEX KEY: 0001838114
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-15006
FILM NUMBER: 24643802
MAIL ADDRESS:
STREET 1: C/O CELLDEX THERAPEUTICS, INC.
STREET 2: 53 FRONTAGE ROAD, SUITE 220
CITY: HAMPTON
STATE: NJ
ZIP: 08827
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Celldex Therapeutics, Inc.
CENTRAL INDEX KEY: 0000744218
STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 133191702
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 53 FRONTAGE ROAD
STREET 2: SUITE 220
CITY: HAMPTON
STATE: NJ
ZIP: 08827
BUSINESS PHONE: 908-200-7500
MAIL ADDRESS:
STREET 1: 53 FRONTAGE ROAD
STREET 2: SUITE 220
CITY: HAMPTON
STATE: NJ
ZIP: 08827
FORMER COMPANY:
FORMER CONFORMED NAME: AVANT IMMUNOTHERAPEUTICS INC
DATE OF NAME CHANGE: 19980828
FORMER COMPANY:
FORMER CONFORMED NAME: T CELL SCIENCES INC
DATE OF NAME CHANGE: 19920703
4
1
form4-02152024_090240.xml
X0508
4
2024-02-13
0000744218
Celldex Therapeutics, Inc.
CLDX
0001838114
Jimenez Freddy A.
C/O CELLDEX THERAPEUTICS, INC.
53 FRONTAGE ROAD, SUITE 220
HAMPTON
NJ
08827
false
true
false
false
SVP & GENERAL COUNSEL
0
Common Stock
2024-02-13
4
M
0
4166
9.0165
A
5924
D
Common Stock
2024-02-13
4
M
0
20000
2.78
A
25924
D
Incentive Stock Option (Right to Buy)
9.0165
2024-02-13
4
M
0
4166
0
D
2028-06-13
Common Stock
4166
0
D
Incentive Stock Option (Right to Buy)
2.78
2024-02-13
4
M
0
20000
0
D
2029-06-19
Common Stock
20000
0
D
On February 8, 2019, Celldex Therapeutics, Inc. effected a 1-for-15 reverse stock split of its common stock (the "Reverse Stock Split"). This option was previously reported as covering 62,500 shares at an exercise price of $0.6011 per share, but has been adjusted to reflect the Reverse Stock Split.
Includes 1,328 shares of common stock acquired under the Celldex Therapeutics, Inc. 2004 Employee Stock Purchase Plan.
As of June 13, 2022, the option is fully vested.
As of June 19, 2023, the option is fully vested.
/s/ Sam Martin, attorney-in-fact for Freddy A. Jimenez
2024-02-15